Trial
NCT01826448
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Daiichi Sankyo
Collaborators
Plexxikon
Condition
V600-mutated BRAF Unresectable Melanoma
Intervention
PLX3397
Why stopped
No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-28